Yazan Migdady, MD
Hematology · Denver, CONPI 1306157458
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,688 of the $13,087 with a category attached, or 66.4%. 14 manufacturers reported payments, led by Syndax Pharmaceuticals, Inc. at 40.0% of the total.
Across 26 payments — averaging $503.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Syndax Pharmaceuticals, Inc.$5K
- Rigel Pharmaceuticals, Inc.$3K
- Medexus Pharma, Inc.$2K
- Servier Pharmaceuticals LLC$2K
- Recordati_rare_diseases_inc.$688
- Jazz Pharmaceuticals Inc.$46
- plus $210 from 8 others
Across 35 payments — averaging $786.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$28K
What the payments were for
- Consulting fees$8,68866%
- Speaking & faculty fees$2,04816%
- Travel & lodging$1,72613%
- Food & beverage$6265%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Syndax Pharmaceuticals, Inc. | 6 | $5,237 |
| Rigel Pharmaceuticals, Inc. | 7 | $2,906 |
| Medexus Pharma, Inc. | 1 | $2,040 |
| Servier Pharmaceuticals LLC | 1 | $1,960 |
| Recordati_rare_diseases_inc. | 1 | $688 |
| Jazz Pharmaceuticals Inc. | 1 | $46 |
| Incyte Corporation | 2 | $45 |
| Geron Corporation | 1 | $38 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $22 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Sobi, Inc | 1 | $21 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 31 | $555 |
Paid to pharmacies, not to this prescriber.
Other hematology in Denver
- Audrey SatoDenver$31
- Tyler BucknerAurora$61K
- Brandon McMahonAurora$9K
- Kathryn HassellAurora$6K
- Ann HeddermanDelta$6K
- Thomas KartikaAurora$360
- Lisa ChuAurora$269
- Sally StablerAurora$140
- Olumide OdeyemiAurora$38
- Chelsea HayesAurora$32
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.